DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Yes, Ozempic and tirzepatide are peptides — that part is true. No, a research-peptide vial labelled 'not for human consumption' is not a cheaper version of the drug. Here is the difference, and how the dosing goes wrong.
Semaglutide is a peptide, a modified version of your own GLP-1 hormone. Tirzepatide is a peptide too, a larger one hitting two receptors at once. So a seller calling their vial a “GLP-1 peptide” is telling the technical truth. The lie is by omission: what makes Wegovy a medicine is not that it is a peptide — it is that a regulator verified the molecule, the dose, the sterility and the factory. Same molecule, no verification, is not a discount. It is a different product that happens to share a name.
Your medication is measured in milligrams. An insulin syringe is marked in units. They are not the same thing, and the number of units that makes up your milligram dose changes with the concentration the powder was mixed to — a 5 mg/mL vial and a 20 mg/mL vial need completely different volumes for the identical dose.
The classic error is quiet and catastrophic: you switch to a more concentrated vial, draw the same number of units you drew last time out of habit, and inject double or quadruple your dose. The FDA has specifically named syringe-size and unit confusion as a common dosing-error pattern with compounded GLP-1s, and tirzepatide overdoses severe enough to require intensive care have been documented in the literature. There is no safe rule of thumb — the unit count that was correct last month can be an overdose this month.
“Cheap” and “grey-market peptide” are not the same trade — you are swapping a known price for an unknown drug. There are legal routes genuinely cheaper than the retail sticker: manufacturer-direct at roughly $499/month, a savings card near $25/month with commercial insurance, and regulated compounding in between. None of them ask you to become your own pharmacist.
Every legal route, ranked by price →Is compounding even legal now?
Yes to both. Semaglutide (Ozempic, Wegovy) is a peptide — a modified analogue of the natural GLP-1 hormone. Tirzepatide (Mounjaro, Zepbound) is also a peptide, a larger one that acts on two receptors at once. So when a grey-market seller calls their vial a "GLP-1 peptide", they are not technically lying about the chemistry. What they are quietly leaving out is everything that makes a medicine a medicine: that the FDA verified the molecule, the dose, the sterility and the manufacturing. A prescription pen and a research-peptide vial can contain the same molecule and still be worlds apart in whether you can trust what is actually in them.
It is raw peptide powder, usually from an overseas chemical supplier, sold to you to reconstitute and inject yourself with no pharmacist and no medical supervision. The "for research purposes only" and "not for human consumption" labels are not a health warning — they are a legal dodge, an attempt to sell an unapproved drug while claiming it is a laboratory reagent. The FDA is not fooled by it: in April 2026 it issued warning letters to seven online peptide sellers for exactly this, and it treats these products as unapproved drugs. The label is there to protect the seller, not you.
You have no way to know, and that is the point. The FDA warns that grey-market GLP-1s are not evaluated for safety, quality or efficacy and may be counterfeit, contaminated or improperly made — meaning the vial can contain the wrong molecule, too little, too much, or none of the active ingredient at all. There is no sterility guarantee for something you mix at your kitchen table. As of July 2025 the FDA had logged over 1,100 adverse-event reports for compounded semaglutide and tirzepatide, and compounded product is at least made in a licensed pharmacy — grey-market peptides are a rung below that, and their harms mostly go unreported because nobody is tracking them.
Because units and milligrams are not the same measurement, and the conversion between them changes with every vial. Your medication is dosed in milligrams; an insulin syringe is marked in units; how many units make up your milligram dose depends entirely on the concentration the powder was reconstituted to. A 5 mg/mL vial and a 20 mg/mL vial need completely different unit volumes for the identical dose. The classic error: you switch to a more concentrated vial, draw the same number of units out of habit, and inject double. The FDA has specifically cited syringe-size and unit confusion as a common dosing-error pattern with compounded GLP-1s, and tirzepatide overdoses severe enough to need intensive care have been documented. There is no safe rule of thumb here — the number of units that was right last month can be an overdose this month.
The honest answer is that "cheap" and "grey-market peptide" are not the same thing — you are trading a known price for an unknown drug. There are legal routes that are genuinely cheaper than the retail sticker: manufacturer-direct programmes (NovoCare, LillyDirect) sell FDA-approved product for roughly $499/month, a manufacturer savings card can reach about $25/month if you have commercial insurance, and regulated 503A/503B compounding sits between those and the grey market. We rank every legal route by actual price. None of them require you to become your own pharmacist.